Dr. Todd D. Tillmanns, MD

Dr. Tillmanns practices at West Cancer Center - East Campus in Germantown, Tennessee.

Dr. Tillmanns' NPI, 1720017577, was assigned on July 2, 2006. Dr. Tillmanns graduated from Creighton University School of Medicine in 1996. Dr. Tillmanns holds Tennessee license 37514.

Dr. Tillmanns' primary practice is West Cancer Center - East Campus, at 7714 Poplar Ave, Germantown, TN 38138 in Shelby County. The practice phone is (901) 683-0055.

Dr. Tillmanns' primary practice is West Cancer Center - East Campus in Germantown, Tennessee. Dr. Tillmanns is also affiliated with Methodist University Hospital. The medical group on file is The West Clinic. Dmand AI also links Dr. Tillmanns to 4 more hospitals, 3 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tillmanns practices, 8 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Tillmanns' primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dmand AI has Dr. Tillmanns' licenses on file in 2 states: Tennessee and Mississippi.

CMS data shows 2,171 Medicare services from Dr. Tillmanns across 24 procedure codes in 2024, for 372 Medicare patients. Medicare paid $133,866 for them.

CMS counts 372 Medicare patients who saw Dr. Tillmanns in 2024. The largest group is 65 to 74, with 181 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tillmanns' median patient age at 63, with 97% women.

In 2024, Dr. Tillmanns wrote 821 Medicare Part D claims for 238 patients. 82% of them were for generic drugs. CMS names the drug for 557 of them, across 19 drugs with 11 or more claims each, at $316,451 in total drug cost. In 2023, CMS named 632 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Tillmanns for performance year 2024. Dr. Tillmanns accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tillmanns as offering telehealth. CMS counts 40 procedures of removal of the uterus by Dr. Tillmanns, more than 98% of the clinicians it reports for that procedure.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 31 papers to Dr. Tillmanns, published from 2012 to 2023. 2015 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Ovarian Neoplasms and Uterine Cervical Neoplasms. Dr. Tillmanns has published most often in Gynecol Oncol. Dr. Tillmanns' most frequent co-authors are Marta Ann Crispens, MD, David K. Gaffney, MD, PhD and Ernest S. Han, MD.

Dmand AI links Dr. Tillmanns to 1 clinical trial. Conditions studied include Carcinoma, Ovarian Epithelial and Fallopian Tube Diseases. Open Payments lists research payments to Dr. Tillmanns that name 1 trial.

CMS Open Payments shows 358 general payments to Dr. Tillmanns from 53 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 78% of the total. GlaxoSmithKline, LLC. paid the most, $54,926. It also lists 1 research payment totaling $2,136 in 2018, naming 1 clinical trial.

Dr. Tillmanns graduated from Creighton University School of Medicine in 1996.